DRONCEF 500mg & 1g Injection (Ceftriaxone) | Pharma Services Group

DRONCEF Injection contains Ceftriaxone, a third-generation cephalosporin antibiotic available in 500mg and 1g strengths for the treatment of susceptible bacterial infections. The supplied packaging identifies DRONCEF as Ceftriaxone 1g Injection and describes it as a Third Generation Cephalosporin Antibiotic for IV use. Drug Regulatory Authority of Pakistan (DRAP) records identify DRONCEF 500mg Injection IV as containing Ceftriaxone (as sodium) and list Seraph Pharmaceutical as the company.

Ceftriaxone 500mg and 1g injections are prescription antibiotics used for a wide range of bacterial infections when injectable antibiotic therapy is clinically indicated. Ceftriaxone works by interfering with bacterial cell-wall synthesis, helping eliminate susceptible bacteria. The appropriate strength, route, dose and duration depend on the type and severity of infection, patient age, weight, kidney and liver function and the treating physician’s clinical judgment. DRAP documentation also confirms the Droncef 1g IV presentation manufactured by Seraph Pharmaceuticals.

Available Strengths

The supplied 1g packaging states “For I.V. Use.” Current Pakistani regulatory records list Droncef 500mg IV and Droncef 1g IV presentations.

Key Benefits

• Contains Ceftriaxone, a third-generation cephalosporin antibiotic.
• Available in 500mg and 1g strengths.
• Provides broad antibacterial activity against many susceptible Gram-positive and Gram-negative bacteria.
• Used for serious and clinically significant bacterial infections requiring antibiotic treatment.
• Convenient injectable formulation for hospital and clinical use.
• The 500mg and 1g presentations allow physicians to select the appropriate strength according to individual treatment requirements.
• Manufactured by Seraph Pharmaceuticals, Pakistan.

How It Works

Ceftriaxone is a third-generation cephalosporin that works by inhibiting bacterial cell-wall synthesis. It binds to bacterial penicillin-binding proteins and interferes with the formation of a stable bacterial cell wall, resulting in the death of susceptible bacteria.

Because Ceftriaxone has activity against a broad range of bacteria, it may be selected for various infections when the causative organisms are susceptible and injectable antibiotic treatment is appropriate.

Uses / Therapeutic Applications

DRONCEF (Ceftriaxone) may be prescribed by a healthcare professional for susceptible bacterial infections, including certain:

• Respiratory tract infections
• Pneumonia
• Urinary tract infections
• Skin and soft-tissue infections
• Intra-abdominal infections
• Bone and joint infections
• Bloodstream infections
• Certain sexually transmitted bacterial infections
• Bacterial meningitis
• Other serious bacterial infections requiring parenteral antibiotic therapy

The exact indication should be determined by the treating physician based on the infection, clinical presentation and, where appropriate, microbiological testing.

Directions for Use

DRONCEF Injection must be prepared and administered by a qualified healthcare professional. The dosage and frequency depend on the patient’s age, weight, type and severity of infection and other clinical factors.

The 500mg and 1g strengths are not interchangeable without medical direction. Follow the approved product information for reconstitution, dilution, compatibility and administration.

The supplied 1g pack is specifically labelled for IV use. Certain Ceftriaxone products may also be available in IM presentations, but the route should always be confirmed from the specific product pack before administration.

Do not self-inject DRONCEF.

Precautions

• DRONCEF is a prescription antibiotic.
• Tell your doctor about previous allergic reactions to Ceftriaxone, cephalosporins, penicillins or other beta-lactam antibiotics.
• Inform your doctor if you have liver or kidney disease.
• Tell your healthcare professional about all medicines you are taking.
• Ceftriaxone should be used only when bacterial infection is suspected or confirmed and antibiotic therapy is appropriate.
• Antibiotics are not effective against viral infections such as common cold or influenza.
• Tell your doctor if you have a history of gastrointestinal disease or antibiotic-associated diarrhea.
• Use during pregnancy or breastfeeding only according to professional medical advice.
• Seek immediate medical attention for difficulty breathing, facial swelling, severe rash or other signs of a serious allergic reaction.

Possible Side Effects

Possible side effects of Ceftriaxone may include diarrhea, nausea, vomiting, abdominal discomfort, headache, rash and pain or irritation at the injection site. Changes in liver enzymes or blood counts may also occur.

Serious reactions are uncommon but can include severe allergic reactions, serious skin reactions and antibiotic-associated colitis. Seek medical attention if severe or persistent diarrhea, significant rash, breathing difficulty or other serious symptoms develop.

Storage Instructions

• Store according to the manufacturer’s recommended storage conditions.
• Keep the unopened vial in its original packaging.
• Protect from excessive heat, moisture and direct sunlight.
• Keep out of reach of children.
• Do not use after the expiry date.
• Reconstituted solutions should be prepared and stored according to the approved product information and healthcare-facility procedures.
• Inspect the prepared solution before administration.

Manufacturer Information

Brand: DRONCEF
Generic Name: Ceftriaxone
Available Strengths: 500mg & 1g
Dosage Form: Powder for Injection
Route: IV
Drug Class: Third-Generation Cephalosporin Antibiotic
Manufacturer: Seraph Pharmaceuticals
Country: Pakistan

DRAP records identify Droncef 500mg Injection IV as Ceftriaxone (as sodium) and list Seraph Pharmaceutical as the company. DRAP registration documentation also identifies Droncef 1g IV as the reference product for another Ceftriaxone 1g presentation, confirming the 1g Droncef presentation.

Product Specifications